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Abstract
Background: Recombinant antibodies can be produced in different formats and different expression systems.
Single chain variable fragments (scFvs) represent an attractive alternative to full-length antibodies and they can be
easily produced in bacteria or yeast. However, the scFvs exhibit monovalent antigen-binding properties and short
serum half-lives. The stability and avidity of the scFvs can be improved by their multimerization or fusion with IgG
Fc domain. The aim of the current study was to investigate the possibilities to produce in yeast high-affinity scFv-
Fc proteins neutralizing the cytolytic activity of vaginolysin (VLY), the main virulence factor of Gardnerella vaginalis.
Results: The scFv protein derived from hybridoma cell line producing high-affinity neutralizing antibodies against
VLY was fused with human IgG1 Fc domain. Four different variants of anti-VLY scFv-Fc fusion proteins were
constructed and produced in yeast Saccharomyces cerevisiae. The non-tagged scFv-Fc and hexahistidine-tagged
scFv-Fc proteins were found predominantly as insoluble aggregates and therefore were not suitable for further
purification and activity testing. The addition of yeast a-factor signal sequence did not support secretion of anti-
VLY scFv-Fc but increased the amount of its intracellular soluble form. However, the purified protein showed a
weak VLY-neutralizing capability. In contrast, the fusion of anti-VLY scFv-Fc molecules with hamster polyomavirus-
derived VP2 protein and its co-expression with VP1 protein resulted in an effective production of pseudotype virus-
like particles (VLPs) that exhibited strong VLY-binding activity. Recombinant scFv-Fc molecules displayed on the
surface of VLPs neutralized VLY-mediated lysis of human erythrocytes and HeLa cells with high potency
comparable to that of full-length antibody.
Conclusions: Recombinant scFv-Fc proteins were expressed in yeast with low efficiency. New approach to display
the scFv-Fc molecules on the surface of pseudotype VLPs was successful and allowed generation of multivalent
scFv-Fc proteins with high VLY-neutralizing potency. Our study demonstrated for the first time that large
recombinant antibody molecule fused with hamster polyomavirus VP2 protein and co-expressed with VP1 protein
in the form of pseudotype VLPs was properly folded and exhibited strong antigen-binding activity. The current
study broadens the potential of recombinant VLPs as a highly efficient carrier for functionally active complex
proteins.
Keywords: Recombinant antibodies, virus-like particles, vaginolysin
* Correspondence: agedv@ibt.lt
1Vilnius University, Institute of Biotechnology, Department of Eukaryote
Genetic Engineering, Graiciuno 8, LT-02241 Vilnius, Lithuania
Full list of author information is available at the end of the article
Pleckaityte et al. Microbial Cell Factories 2011, 10:109
http://www.microbialcellfactories.com/content/10/1/109
© 2011 Pleckaityte et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Background
Recombinant antibodies are widely used in therapeutic,
diagnostic and research settings. Different variants of
recombinant antibodies have been described to date. Chi-
meric and humanized antibodies represent important
biopharmaceutical products for the immunotherapy of
malignant and inflammatory diseases [1]. The advantage
of full-length recombinant immunoglobulin molecule is
its ability to perform both antigen-binding and effectors’
functions. For some applications, functionally active
recombinant antibody fragments instead of full-length
antibodies can be used. Single chain variable fragments
(scFvs) remain attractive recombinant molecules because
of their selection in vitro approaches, lack of glycosyla-
tion, small size and tissue penetration efficacy, lower
immunogenicity as a result of elimination of constant
domains of the antibody, easier and less costly manufac-
ture [2,3]. The scFv consists of variable regions of light
(VL) and heavy (VH) immunoglobulin chains forming
antigen-binding domains engineered into a single poly-
peptide [4]. VL and VH regions are usually joined by a
flexible linker sequence. The scFvs are mainly produced
as monomeric structures displaying monovalent antigen-
binding activity. However, the lack of Fc domain impairs
the stability of the scFv molecule. As a consequence, the
scFvs are rapidly degraded in serum and have short circu-
lating half-lives [5]. Several strategies have been used to
circumvent the drawbacks of scFvs and obtain better
clearance properties. Further engineering allowed form-
ing of multivalent antibody fragments (diabodies, triabo-
dies) with single or multiple specificities to different
target antigens [6]. An alternative approach includes scFv
fusion with IgG Fc domain leading into IgG-like format
[7-9]. In addition, the scFv being a monomer molecule
after the fusion with Fc regains the avidity because of
dimerization [9]. Taken together, scFv-Fc fusion protein
retains the affinity and specificity of the parent scFv
along with the prolonged serum half-life and bivalent
binding [7].
Recombinant full-length immunoglobulins are usually
produced in eukaryote cells. Mammalian expression sys-
tems ensure proper folding and post-translational modifi-
cation of recombinant antibodies. However, the main
disadvantages of cell cultures are low expression levels,
expensive and time-consuming production of recombi-
nant proteins [10]. The employment of yeast and plant
expression systems for the generation of humanized
recombinant antibodies has also been demonstrated
[11-15]. For the production of antibody fragments (scFv,
Fab fragments, diabodies) yeast and bacterial cells are
widely used because recombinant antibody fragments do
not require glycosylation for their biological activities and
are relatively easily assembled [16]. However, often
introduction of different modifications in yeast or E. coli
cells is necessary to optimize the expression of antibody
fragments. For example, remarkably increased production
of scFv in Saccharomyces cerevisiae was obtained when
two chaperones were overexpressed together with scFv
and yeast growth temperature was reduced [17]. An
alternative approach to overcome aggregation leading to
subsequent degradation of scFv expressed in S. cerevisiae
may be the presentation of scFv molecules on the surface
of virus-like particles (VLPs) as we demonstrated in the
current study.
Recently, we have developed neutralizing monoclonal
antibodies (MAbs) against the protein toxin vaginolysin
(VLY), the main virulence factor of Gardnerella vaginalis
[18]. VLY belongs to the cholesterol-dependent cytoly-
sins (CDCs), a family of pore-forming toxins [19]. These
toxins cause lysis of cellular membrane and are thought
to play a key role in the virulence of bacteria [20]. The
MAbs against VLY were shown to bind the toxin with
high affinity and inhibit VLY-mediated hemolysis of
human erythrocytes [18]. Inhibition of cytolytic activity
of VLY may have important physiologic relevance, as the
lysis of vaginal epithelial cells by VLY is considered to be
a key step in progression of bacterial vaginosis and pre-
dispose to the disease-associated complications [21].
In the present study, the scFv derived from hybridoma
cell line producing high-affinity neutralizing MAbs
against VLY [18] was fused with human IgG1 Fc domain
comprising the CH2 and CH3 domains and the hinge
region [9]. We have expressed the anti-VLY scFv-Fc con-
struct in yeast S. cerevisiae in four different formats and
demonstrated that pseudotype VLPs consisting of ham-
ster polyomavirus (HaPyV)-derived capsid proteins
represented highly efficient carrier for a functionally
active scFv-Fc molecules with VLY-neutralizing activity.
Results
Expression of anti-VLY scFv-Fc constructs in yeast
For the production of anti-VLY scFv fused to a human
IgG1 Fc domain in yeast, the expression plasmids encod-
ing different scFv-Fc variants (Figure 1A) were con-
structed: (i) non-tagged scFv-Fc, (ii) scFv-Fc harboring
the hexahistidine tag (His-tag) at the N-terminus (His-
scFv-Fc), (iii) scFv-Fc harboring yeast a-factor signal
sequence at the N-terminus (aF-scFv-Fc). The respective
DNA sequences were cloned into yeast expression vector
pFX7 [22] and transformed into yeast S. cerevisiae.T h e
addition of His-tag sequence was considered to be useful
for further purification of recombinant scFv-Fc protein.
Yeast a-factor signal sequence was added in order to
direct the secretion of anti-VLY scFv-Fc to the growth
medium that may significantly simplify purification pro-
cedure of the recombinant protein.
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the control of an inducible galactose promoter. The
expression of all recombinant anti-VLY scFv-Fc con-
structs was analyzed in yeast strain AH22-214 and its
derivative AH22-214p lacking peptidase Pep4 both by
gel electrophoresis (SDS-PAGE) and Western blot using
anti-human IgG conjugated to horse-radish peroxidase
(HRP). The production of recombinant anti-VLY scFv-
Fc proteins were detected only in yeast strain AH22-
214p. No expression of the anti-VLY scFv-Fc constructs
in yeast strain AH22-214 cells was detected (data not
shown).
The non-tagged anti-VLY scFv-Fc fusion protein
(molecular mass of approximately 51 kDa) was not visi-
ble in SDS-PAGE (Figure 2A) but was detected with
HRP-labeled anti-human IgG as a faint a band in the
whole crude lysate of transformed yeast strain AH22-
214p cells (Figure 2B, lane 2) and its soluble and insolu-
ble fractions (Figure 2B, lanes 3, 4). However, the
expression level of the soluble anti-VLY scFv-Fc protein
in yeast strain AH22-214p was too low for further puri-
fication and functional studies. The obtained results
demonstrated low efficiency of yeast expression system
for the production of the non-tagged anti-VLY scFv-Fc
construct.
The addition of His-tag sequence to the N-terminus of
anti-VLY scFv-Fc construct resulted in higher expres-
sion level as compared to the non-tagged protein. The
His-scFv-Fc protein was detected both by SDS-PAGE
and Western blot in the whole crude lysate of trans-
formed yeast AH22-214p cells (Figure 2C, D, lane 2).
However, the main part of His-scFv-Fc was found in the
insoluble fraction of yeast cell lysate (Figure 2C, D, lane
4). The level of anti-VLY His-scFv-Fc in the soluble
fraction of yeast cell lysate was considered as insufficient
for further purification and activity testing.
It was expected that yeast a-factor signal sequence
added to the N-terminus of scFv-Fc will assist the secre-
tion of recombinant protein aF-scFv-Fc into yeast
growth medium. However, the aF-scFv-Fc protein was
not detected in yeast growth medium analyzed both by
SDS-PAGE and Western blot (data not shown). Never-
theless, addition of yeast a-factor signal sequence
improved the intracellular production of anti-VLY scFv-
Fc. A protein band of approximately 60 kDa corre-
sponding to the aF-scFv-Fc was found in the soluble
fraction of yeast cell lysate examined both by SDS-
PAGE and Western blot (Figure 2E, F, lane 3). The
amount of soluble aF-scFv-Fc protein was sufficient for
purification and further activity testing. The soluble
fraction of yeast cell lysate was collected and anti-VLY
aF-scFv-Fc protein was purified using affinity chromato-
graphy on protein A which binds the Fc domain of the
target protein (Figure 2E, F, lane 4). Western blot analy-
sis of unpurified as well as purified anti-VLY aF-scFv-Fc
protein revealed two immunostained bands of approxi-
mately 60 and 70 kDa (Figure 2F, lane 4). The principal
band of 60 kDa represents anti-VLY aF-scFv-Fc protein
with unprocessed yeast a-factor signal sequence at the
N-terminus. The protein fraction of 70 kDa most likely
represents glycosylated form of the aF-scFv-Fc protein
with unprocessed yeast a-factor signal sequence at the
N-terminus. Although the anti-VLY aF-scFv-Fc protein
demonstrated better stability than non-tagged scFv-Fc
or His-scFv-Fc proteins, the immunoreactive 30 and 25
kDa bands detected by Western blot in the purified
Figure 1 Schematic representation of anti-VLY scFv-Fc constructs expressed in yeast.
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Page 3 of 13Figure 2 Analysis of the production of anti-VLY scFv-Fv, His-scFv-Fv and aF-scFv-Fv proteins in yeast strain AH22-214p.( A ,C ,E ) :
Coomassie blue-stained SDS-PAGE; (B, D, F): Western blot with HRP-labeled secondary antibody against human IgG. (A, B): In lanes: 2-whole
crude lysate of yeast transformed with pFX7-scFv-Fc plasmid, 3-the soluble fraction recovered after centrifugation of whole crude lysate of yeast
transformed with pFX7-scFv-Fc plasmid, 4-pellet recovered after centrifugation of whole crude lysate of yeast transformed with pFX7-scFv-Fc
plasmid. (C, D): In lanes: 2-whole crude lysate of yeast transformed with pFX7-His-scFv-Fc plasmid, 3-the soluble fraction recovered after
centrifugation of crude lysate of yeast transformed with pFX7-His-scFv-Fc plasmid, 4-pellet recovered after centrifugation of crude lysate of yeast
transformed with pFX7-His-scFv-Fc plasmid. (E, F): In lanes: 2-whole crude lysate of yeast transformed with pFX7-aF-scFv-Fc plasmid, 3-the
soluble fraction recovered after centrifugation of crude lysate of yeast transformed with pFX7-aF-scFv-Fc plasmid, 4-aF-scFv-Fc purified using
protein A Sepharose (lane 4). In all gels negative control sample of whole crude lysate of S. cerevisiae cells, transformed with empty vector pFX7
was loaded on lane 1 and pre-stained protein weight marker (Thermo Scientific Fermentas) was loaded on lane M.
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ducts. These data confirmed the tendency of yeast-
expressed scFv-Fc proteins to degradation.
Expression of anti-VLY scFv-Fc construct displayed on the
surface of pseudotype VLPs
In order to improve the expression level of anti-VLY
scFv-Fc in yeast, as well as to reduce its instability and
insolubility a new approach was applied. The gene
encoding anti-VLY scFv-Fc protein was fused with gene
encoding modified HaPyV-derived minor capsid protein
VP2 and co-expressed in yeast strain AH22-214p
together with HaPyV gene encoding the major capsid
protein VP1 (Figure 1B). The production of both VP1
and VP2-scFv-Fc proteins was induced by adding galac-
tose. After induction of the synthesis of VP1 and VP2-
scFv-Fc proteins the lysate of harvested yeast cells was
examined both by SDS-PAGE and Western blot. The
analysis of yeast cell lysate by SDS-PAGE revealed a
protein band of approximately 42 kDa that was identi-
fied as an intact VP1 protein (Figure 3A, lanes 2, 3). In
the Western blot a protein band of approximately 80
kDa corresponding to the molecular mass of anti-VLY
VP2-scFv-Fc fusion protein was detected (Figure 3B,
lanes 2, 3). Polyclonal antibodies against HaPyV VP1
and VP2 proteins immunostained the same 80 kDa and
42 kDa bands corresponding to the VP2-scFv-Fc and
VP1 proteins, respectively (Figure 3C, lanes 2, 3).
The VP1/VP2-scFv-Fc proteins generated in yeast were
successfully purified by the method adapted for the puri-
fication of VLPs using sucrose and CsCl density centrifu-
gation. The analysis of purified VP1/VP2-scFv-Fc
Figure 3 Analysis of the expression of anti-VLY VP1/VP2-scFv-Fv pseudotype VLPs in yeast. (A): Coomassie blue-stained SDS-PAGE; (B):
Western blot with HRP-conjugated anti- human IgG; (C): Western blot with mouse polyclonal antibodies against VP1/VP2 VLPs. The same
samples were run on each gel. In lanes: 1-negative control sample from whole crude lysate of S. cerevisiae cells, transformed with empty vector
pFX7; 2-whole crude lysate of yeast transformed with pFGG3-VP1/VP2-scFv-Fc plasmid, 3-the soluble fraction recovered after centrifugation of
crude lysate of yeast transformed with pFGG3-VP1/VP2-scFv-Fc plasmid, 4-VLPs consisting of VP1 protein and fusion protein VP2-scFv-Fc purified
using sucrose and CsCl gradients; M-pre-stained protein weight marker (Thermo Scientific Fermentas). (D): Electron microscopy pictures of VP1/
VP2-scFv-Fv pseudotype VLPs, stained with 2% aqueous uranyl acetate solution and examined by Morgagni 268 electron microscope.
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two expected homogenous protein bands (Figure 3A, B,
C, lane 4). The purified VP1/VP2-scFv-Fc proteins were
negatively stained and subjected to electron microscopy
examination. It was determined that the VP1/VP2-scFv-
Fc proteins efficiently self-assembled into so-called
“pseudotype” VLPs (consisting of intact VP1 and modi-
fied VP2 viral proteins) similar in their size and shape to
unmodified HaPyV-VP1 VLPs. The diameter of recombi-
nant pseudotype VLPs was 45-50 nm, which is typical for
polyomavirus capsid (Figure 3D). It was calculated that
approximately 19 scFv-Fc molecules were displayed on
one pseudotype VLP.
Neutralizing activity of the aF-scFv-Fc protein and
pseudotype VLPs harboring scFv-Fc
Antigen-binding activity of anti-VLY aF-scFv-Fc protein
eluted from protein A-Sepharose column as well as puri-
fied pseudotype VLPs harboring scFv-Fc was demon-
strated by an indirect ELISA using both anti-human IgG
and anti-mouse IgG secondary antibody (data not shown).
The ability of the anti-VLY aF-scFv-Fc protein purified by
affinity chromatography and scFv-Fc displayed on the sur-
face of recombinant VP1/VP2-scFv-Fc pseudotype VLPs
to inhibit the hemolytic activity of VLY was assayed in
vitro using human erythrocyte suspension.
Anti-VLY aF-scFv-Fc protein was used at the concen-
trations ranging from 3.6 ng/mL (6 × 10
-11 M) to 0.54 μg/
mL (8.96 × 10
-9 M) and the recombinant VLY was used at
the concentration of 5 ng/mL (8.5 × 10
-11 M) that was
proven to be sufficient for a complete lysis of human ery-
throcytes [18]. However, anti-VLY aF-scFv-Fc protein
induced only partial neutralization of the VLY activity.
Even at high concentrations of the aF-scFv-Fc protein
(540 ng/mL or 8.96 × 10
-9 M) its inhibitory effect did not
exceed 60% (Figure 4A) of that observed with 20 ng/mL
(1.33 × 10
-10 M) of full-length parental antibody clone 9B4
(Figure 4B). Most probably, the incomplete neutralization
of the VLY activity was caused by a lower affinity of the
monovalent aF-scFv-Fc construct as compared to the full-
length antibody.
In contrast, the scFv-Fc molecule fused with VP2 pro-
tein and presented on the surface of pseudotype VP1/VP2
VLPs was functionally active and inhibited the cytolytic
activity of VLY with high efficiency. Complete neutraliza-
tion of VLY in the in vitro hemolytic assay was observed
at concentrations of chimeric VP2-scFv-Fc protein exceed-
i n g1 2n g / m Lo r1 . 5×1 0
-10 M (Figure 4C). Thus, the
VLY-neutralizing potency of VP1/VP2-scFv-Fc was com-
parable to that obtained with 20 ng/mL or 1.33 × 10
-10 M
of full-length parental MAb 9B4 (Figure 4B).
The neutralizing activity of anti-VLY scFv-Fc displayed
on the surface of recombinant VP1/VP2-scFv-Fc pseudo-
type VLPs was also tested in additional in vitro cytolytic
assay using human cervical epithelial HeLa cell line and
demonstrated high VLY-neutralizing potency of anti-
VLY VP1/VP2-scFv-Fc VLPs comparable to that of full-
length MAb 9B4. The extent of the VLY-mediated lysis
of HeLa cells was evaluated by colorimetric MTS assay. It
was determined that 3 μg/mL (3.8 × 10
-8 M) of the
chimeric VP2-scFv-Fc protein displayed on VP1/VP2-
scFv-Fc VLPs induced complete neutralization of the
VLY-mediated cytolysis as effective as 50 μg/mL or 3.3 ×
10
-7 M full-length anti-VLY antibody 9B4 (Figure 4D).
Discussion
Yeast is attractive host for production of heterologous
proteins [23]. The main advantages of the production of
recombinant antibodies in yeast are the possibilities to
use cheap, defined growth media and generate high cell
densities in short cultivation times [24]. Previous studies
show that scFv-Fc proteins assemble in yeast easier when
compared to bacterial expression systems [7,25-27]. In
line with these data, our attempts to express anti-VLY
scFv-Fc construct in E. coli were unsuccessful-the scFv-
Fc protein was found to be insoluble and the efforts for
its refolding were inefficient (data not shown). Therefore,
in the current study yeast expression system has been
selected for the synthesis of anti-VLY scFv-Fc protein.
To obtain functionally active scFv-Fc protein in yeast,
four scFv-Fc constructs were generated: non-tagged
scFv-Fc, His-scFv-Fc, aF-scFv-Fc and VP1/VP2-scFv-Fc
assembled into pseudotype VLPs (Figure 1). As the anti-
VLY scFv-Fc constructs were not detectable after induc-
tion in yeast strain AH22-214 containing an intact yeast
peptidase Pep4, we hypothesize that these constructs
were highly sensitive to proteolysis. In contrast, the
expression of all four constructs was obtained in the
yeast strain AH22-214p where Pep4 peptidase was
deleted. Despite different expression levels of non-tagged
scFv-Fc, His-scFv-Fc and aF-scFv-Fc, a major part of all
these proteins was found as insoluble aggregates what
could be associated with protein misfolding (Figure 2). It
is considered that the exposure of the hydrophobic sur-
faces on the VL and VH chains of scFv plays an impor-
tant role in its aggregation in the yeast cell [28]. The
hydrophobic regions of the scFv molecule responsible for
keeping the variable regions of the heavy and light chains
together could also interact with other molecules in the
cell. The aggregation of scFv molecules in S. cerevisiae
may also result in their subsequent degradation because
of induction of the unfolded protein response [29,30]. In
agreement with these reports, our attempts to express in
yeast the non-tagged scFv-Fc protein were unsuccessful.
Although the expression of the scFv-Fc was improved
after adding the His-tag at its N-terminus, the amount of
the soluble form of His-scFv-Fc protein remained too
low for further processing. It was anticipated that the
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the secretion of the soluble form of scFv-Fc protein.
However, despite the fact that the part of the aF-scFv-Fc
protein was found in the soluble cell lysate (Figure 2F,
lanes 2, 3, 4), the recombinant protein was not detected
in yeast growth medium. Most likely the secretion of the
aF-scFv-Fc protein was hampered by its improper folding
and aggregates were formed in the ER and vacuolar-like
organelles as demonstrated for other recombinant pro-
teins in yeast [28]. Surprisingly, the intracellular produc-
tion of the aF-scFv-Fc protein was improved and the
amount of its soluble form was sufficient for purification.
Although yeast a-factor signal sequence stabilized
recombinant aF-scFv-Fc protein, it also might interfere
with the scFv fragment and reduce the affinity of scFv-Fc
to its target. Another reason why the aF-scFv-Fc protein
demonstrated a weak VLY-neutralizing activity as com-
pared to the full-length antibody 9B4 could be the mono-
valent structure or irregularly aggregated form of the
purified aF-scFv-Fc protein.
To improve the stability and binding properties of
anti-VLY scFv-Fc protein we have applied a new
approach for its expression in yeast. The scFv-Fc mole-
cule was fused with HaPyV-derived minor capsid pro-
tein VP2 and expressed on the surface of HaPyV-
derived pseudotype VLPs consisting of capsid proteins
VP1 and VP2. Polyomaviruses are nonenveloped viruses
with an icosahedral capsid, approximately 45 nm in
Figure 4 Inhibition of VLY-mediated cytolysis by anti-VLY aF-scFv-Fc, mAb 9B4 and pseudotype VP1/VP2-scFv-Fc VLPs.( A ,B ,C ) :T h e
inhibition of VLY-mediated lysis of human erythrocytes (% of hemolysis cells) was evaluated after addition of human erythrocyte suspension to
VLY (5 ng/ml) pre-incubated with (A): aF-scFv-Fc protein at concentrations ranging from 3.6 ng/ml (6 × 10
-11 M) to 540 ng/ml (8.96 x10
-9 M); (B):
MAb 9B4 at concentrations ranging from 1 ng/ml (6.7 × 10
-11 M) to 200 ng/ml (1.33 × 10
-9 M); (C): VP1/VP2-scFv-Fc VLPs at concentrations of
VP2-scFv-Fc protein ranging from 1 ng/ml (1.25 × 10
-11 M) to 33 ng/ml (4.1 × 10
-10 M). (D): The inhibition of VLY-mediated lysis of human
cervical epithelial HeLa cells was evaluated after their exposure to VLY alone (3 μg/ml) or VLY (3 μg/ml) preincubated either with VP1/VP2-scFv-
Fc VLPs (VP2-scFv-Fc concentration 3 μg/ml or 3.8 × 10
-8 M) or MAb 9B4 (50 μg/ml or 3.33 x10
-7 M). Cell viability was determined by
colorimetric assay using MTS staining. Values were normalized to 100% for each assay.
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40 [31] and murine polyomavirus [32] have been
resolved, it is known that the capsid of polyomaviruses
mainly consists of 72 pentamers formed by 360 copies
of the VP1 protein. One minor capsid protein, either
VP2 or VP3, binds in the central 5-fold cavity of each
VP1 pentamer [33]. VLPs can be efficiently produced by
heterologous expression of one or more viral structural
proteins which spontaneously self-assemble into struc-
tures usually similar to the authentic viruses they are
derived from, but non-infectious because they are free
of viral genetic material [34]. The capability of recombi-
nant polyomavirus-derived capsid proteins to form VLPs
has been demonstrated in earlier reports [35]. Our pre-
vious studies show that HaPyV-derived VLPs represent
a useful tool for protein engineering. HaPyV VP1 VLPs
are powerful vehicles for the foreign peptides of interest
as they tolerate inserts of different size and origin (from
9 to 120 amino acid (aa)-long) at certain VP1 sites
[36-38]. The assembly capacity of HaPyV VP1 protein
and its interaction with the VP2 protein which was
fused to the anti-VLY scFv-Fc sequence was exploited in
this study for the production of pseudotype VLPs exhi-
biting VLY-binding activity.
It was known that the C-terminal part of VP2 protein
was necessary for interaction with VP1 pentamer [33]
therefore, VP2 N-terminus was used to join the scFv-Fc
molecule. For this purpose, 100 aa from N-terminus of
VP2 protein was deleted and replaced with anti-VLY
scFv-Fc expecting that recombinant antibody fragments
will be displayed on the surface of VLPs. Subsequent
purification of recombinant proteins by density ultracen-
trifugation adapted for VLP purification and electron
microscopy analysis confirmed that pseudotype VP1/
VP2-scFv-Fc VLPs were efficiently produced in yeast S.
cerevisiae. As maximum 72 minor capsid proteins, either
VP2 or VP3 could be included into VP1/VP2 VLP [33]
consequently up to 72 chimeric VP2-scFv-Fc molecules
might be incorporated into one VLP. However, the
attachment of large fusion protein on the surface of
pseudotype VLP readjusted the quantity of VP2-scFv-Fc
to approximately 19 molecules per VLP. The different
production levels of co-expressed VP1 and VP2-scFv-Fc
proteins (what is very conducive to the VP1/VP2-scFv-
Fc pseudotype VPL formation) was ensured by using the
pFGG3 vector [39]. The pFGG3 vector is equipped with
two promoters induced to different degrees because of
the shortage of Gal4 activator in yeast cells.
The incorporation of VP2-scFv-Fc into pseudotype
VLPs prevented scFv-Fc misfolding and aggregation as
there was no protein solubility problem during purifica-
tion of VLPs. Furthermore, it was demonstrated that
anti-VLY scFv-Fc molecules displayed on the surface of
VLPs were stable and functionally active in all used
applications. VP1/VP2-scFv-Fc VLPs inhibited VLY-
mediated cell lysis with high efficiency comparable to
that of full-length 9B4 antibody. High neutralizing activ-
ity of VP1/VP2-scFv-Fc could be explained by its multi-
meric structure and presentation of approximately 19
scFv-Fc molecules on the surface of one pseudotype
VLP what regained the avidity to VLY similar to that
observed with full-length antibody [18]. The scFv-Fc dis-
played on VP1/VP2-scFv-Fc VLPs not only showed
VLY-binding activity but also were recognized by both
anti-mouse IgG and anti- human IgG secondary anti-
body in ELISA confirming that all parts of the scFv-Fc
molecule were properly folded and active antibody frag-
ments were exposed on the surface of VLPs.
Conclusions
Production of recombinant anti-VLY scFv-Fc proteins in
yeast was tackled with problems of their stability, solubi-
lity and weak VLY-neutralizing activity. The addition of
yeast a-factor signal sequence did not support the secre-
tion of anti-VLY scFv-Fc protein but increased the level
of its intracellular soluble form. An approach to express
anti-VLY scFv-Fc molecules displayed on the surface of
HaPyV-derived VLPs allowed generation of novel func-
tionally active proteins with multivalent VLY-binding
capacity, prevented scFv-Fc aggregation and improved
expression. Our study demonstrated for the first time
that large (472 aa long) complex protein such as recom-
binant antibody fused with HaPyV-derived VP2 protein
and displayed on the surface of pseudotype VP1/VP2
VLPs was properly folded and exhibited a strong anti-
gen-binding activity. Taken together, these data show
that HaPyV-derived pseudotype VP1/VP2-scFv-Fc VLPs
represent a successful alternative for the generation of
multivalent antibody molecules in yeast S. cerevisae and
broadens the potential of HaPyV-derived VLPs as a
highly efficient carrier for functionally active complex
proteins.
Methods
Generation of yeast expression plasmids
All DNA manipulations were carried out according to
standard procedures [40]. Enzymes and kits for DNA
manipulations were purchased from Thermo Scientific
Fermentas (Vilnius, Lithuania). Recombinants were
screened in E. coli DH10B cells. The yeast expression
vector pFX7 for target protein expression was previously
described [22]. Vector pFGG3-VP1/VP2Bg used for tar-
get protein fusion with VP2 protein was constructed by
inserting DNA sequence encoding HaPyV VP1 into
GAL7 expression cassette and modified HaPyV VP2
gene under GAL10-PYK1 hybrid promoter into pFGG3
plasmid [39]. The 1-100 aa encoding sequence in modi-
fied VP2 protein was deleted and GSS linker encoding
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minus was introduced for fusion with target protein
encoding sequence.
DNA sequences encoding the anti-VLY scFv were
cloned from hybridoma 9B4 producing neutralizing
MAbs against VLY [18]. The anti-VLY scFv comprising
variable regions of mouse IgG heavy (VH) (GenBank
JF951748), and light chains (VL) (GenBank JF951747) in
the orientation of VL-linker 20 aa-VH was fused with
the Fc region of human immunoglobulin G1 encoded in
pFUSE-hIgG1-Fc2 vector [9]. The resulting construction
obtained by fusion of anti-VLY scFv to human Fc region
was named anti-VLY scFv-Fc. Four yeast expression
plasmids carrying the anti-VLY scFv-Fc DNA fragment
were generated.
Construction of pFX7-scFv-Fc plasmid
The scFv-encoding DNA fragment was amplified to intro-
duce EcoRV and BcuI sites at the 5’-end and BglII site at
the 3’-end of the PCR fragment using 5’-CGGATATCAC-
TAGTTATGGATATTGTGATGACACAGAC and 5’-
ATGAGATCTTGAGGAGACGGTGACTGAGGT pri-
mers (restriction enzyme sites underlined). The obtained
PCR product was sequenced, digested with EcoRV and
BglII and fused with human Fc-encoding region by cloning
into EcoRV-BglII digested pFUSE-hIgG1-Fc2 vector [9].
The resulting DNA sequence encoding scFv-Fc fuse was
cut out with BcuI-NheI and subcloned into the XbaI site
of the yeast expression vector pFX7. The pFX7-scFv-Fc
plasmid was used for the expression of non-tagged scFv-
Fc construct.
Contruction of pFX7-His-scFv-Fc plasmid
The His-tag sequence (presented in italic) was added in-
frame into the 5’-end of the scFv-encoding fragment by
PCR using the oligonucleotide primers 5’-CGGATAT-
CACTAGTTATGCACCACCACCACCATCACGATAT
TGTGATGACACAGACTAC and 5’-ATGAGATCTT-
GAGGAGACGGTGACTGAGGT. The 5’-end PCR pri-
mer carries EcoRV and BglII sites (underlined) on 5’-end
and 3’-end PCR primer appends BglII site (underlined) on
3’-end of the scFv-Fc for fusion with Fc-encoding region
in pFUSE-hIgG1-Fc2 vector. The DNA sequence encoding
His-tagged scFv-Fc was cut out with BcuI-NheI and sub-
cloned into XbaI digested pFX7 to generate plasmid
pFX7-His-scFv-Fc. The pFX7-His-scFv-Fc plasmid was
used for the expression of scFv-Fc construct with His-tag
at the N-terminus (His-scFv-Fc).
Construction of pFX7-aF-scFv-Fc plasmid
A plasmid containing yeast a-factor signal sequence was
used as a template for amplification by PCR using pri-
mers containing BcuI and AarI (underlined) cleavage
sites 5’-GCTGATCACTAGTTATGAGATTTCCTT-
CAATTTTTACTG and 5’-GCACCTGCACTCTCTTT-
TATCCAAAGATACCCCTTC. Respectively, AatI site
was introduced into 5’-end of scFv DNA fragment by
PCR and fused with a-factor signal sequence. The coding
sequences for a-factor and scFv were sequenced to
exclude PCR-prone errors. The BglII-MlsI digested Fc
coding DNA sequence was fused with a-scFv and the
resulting DNA fragment a-scFv-Fc was cloned into the
XbaI site of pFX7 to generate plasmid pFX7-aF-scFv-Fc.
This plasmid was used for the expression of scFv-Fc con-
struct containing yeast a-factor signal sequence at its N-
terminus (aF-scFv-Fc).
Construction of pFGG3-VP1/VP2-scFv-Fc plasmid
The Fc fragment-coding sequence was amplified to
remove stop codon at the 3’-end and introduce XbaI and
BamHI sites (underlined) at the 5-’ and 3’-ends of the PCR
fragment, respectively, using primers 5’-CGTCTAGAC-
GATATCGGCCATGGTTAGATCTG and 5’-CAG-
GATCCGAACCTCTTGGAACCAATTTACCCGGAGA-
CAGGGAGAGGCTC. The resulting DNA fragment
verified by sequencing was cloned into the XbaI and BglII
sites for fusion to modified HaPyV VP2-encoding
sequence in pFGG3-VP1/VP2Bg vector. The scFv encod-
ing fragment digested with BcuI and BglII as described
above was cloned into pFGG3-VP1/VP2 plasmid carrying
the sequence encoding chimeric Fc-VP2 protein. The plas-
mid pFGG3-VP1/VP2-scFv-Fc was used for the co-expres-
sion of chimeric VP2-scFv-Fc and VP1 proteins in yeast.
Yeast strains, growth media and cultivation conditions
The resulting plasmids pFX7-scFv-Fc, pFX7-His-scFv-Fc,
pFX7-aF-scFv-Fc and pFGG3/VP1-VP2-Fv-Fc-VP2 were
used for the transformation of S. cerevisiae strain AH22-
214 (a, leu2-3,112, his4-519) and its derivative AH22-214p
(a, leu2-3,112 his4-519, ura3, Δpep4) lacking peptidase
Pep4. Yeast transformants harboring plasmids with scFv-
Fc encoding genes were grown in YEPD medium (yeast
extract 1%, peptone 2%, and glucose 2%) supplemented
with 5 mM formaldehyde overnight at 30°C and recombi-
nant protein expression was induced after transferring
yeast cells into induction medium YEPG (yeast extract 1%,
peptone 2%, and galactose 3%) supplemented with 5 mM
formaldehyde and culturing for additional 18 h. Yeast bio-
mass harboring recombinant proteins was harvested by
centrifugation and was stored at -20°C. Yeast transformed
with vector pFX7 or pFGG3 without any insert was used
as a negative control.
SDS-PAGE and Western blotting
Proteins were analyzed by electrophoresis on 12.5%
sodium dodecylsulfate-polyacrylamide gels (SDS-PAGE)
followed by Coomassie brilliant blue staining. Briefly, 20-
50 mg of yeast cell pellets were collected by centrifuga-
tion, washed with distilled water and suspended in 20-50
μL of DB 150 buffer (150 mM NaCl, 1 mM CaCl2,
0.001% Trition X-100, 0.25 M L-Arginine in 10 mM
Tris/HCl-buffer, pH 7.2). An equal volume of glass beads
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with cooling on ice for 1 min between each vortexing
step. The samples of whole yeast lysates, the supernatant
and pellets obtain after centrifugation of whole yeast
lysate or purified proteins were mixed with the SDS-
PAGE sample buffer (Thermo Scientific Fermentas),
boiled for 5 min, applied to a SDS-PAGE and run in
SDS-Tris-glycine buffer. Protein bands in SDS-PAGE
were visualized by staining with Coomassie brilliant blue
(Sigma-Aldrich, St. Louis, MO, USA) or electro-trans-
ferred to Immobilon P membrane (Millipore, Bedford,
MA, USA). The membranes were blocked with 5% milk
in phosphate-buffered saline (PBS) for 2 h at room tem-
perature (RT). Blocking solution was removed and the
membranes were incubated for 1 h at RT with horserad-
ish peroxidase (HRP) conjugated rabbit polyclonal anti-
bodies against human IgG (Bio-Rad, Hercules, CA, USA)
diluted 1:2000 in PBS with 0.1% Tween 20 (PBST) or
mouse polyclonal antibodies against HaPyV VP1/VP2
VLPs generated in-house and diluted 1:1000 in PBST.
For the identification of VP1/VP2-scFv-Fc protein the
membrane before developing was additionally incubated
with HRP-conjugated goat anti-mouse IgG (Bio-Rad)
diluted 1:1000 in PBST. The enzymatic reaction was
developed using tetramethylbenzidine (TMB) chromo-
genic substrate (Sigma-Aldrich).
Purification of aF-scFv-Fc protein and pseudotype VLPs
harboring scFv-Fc
S. cerevisiae yeast biomass harboring recombinant pro-
teins, was suspended and homogenized in DB450 buffer
(450 mM NaCl, 1 mM CaCl2, 0.001% Trition X-100, 0.25
M L-Arginine in 10 mM Tris/HCl-buffer pH 7.2) contain-
ing 2 mM PMSF, EDTA-free Complete Protease Inhibitor
Cocktail (Thermo Scientific Fermentas) and mechanically
disrupted using French press.
Purification of the aF-scFv-Fc protein
After centrifugation of yeast lysate the supernatant con-
taining the aF-scFv-Fc protein was collected and loaded
onto the protein A Sepharose column (rProtein A Sephar-
ose Fast Flow, GE Healthcare, Sweden) equilibrated with
0.1 M Tris-HCl (pH 8.0) buffer. The column was washed
with 0.1 M Tris-HCl (pH 8.0) followed by a wash step
with 0.01 M Tris-HCl (pH 8.0). The elution was
performed with 0.05 M Glycine-HCl (pH 3.0) buffer. Frac-
tions were collected and the presence of the functionally-
active aF-scFv-Fc protein was verified by an indirect
ELISA. The fractions containing purified aF-scFv-Fc were
pooled and dialyzed against PBS.
Purification of pseudotype VLPs harboring scFv-Fc
After centrifugation of yeast lysate, the supernatant con-
taining VP1/VP2-scFv-Fc proteins was collected and
loaded onto a 20-69% sucrose gradient. Subsequently, a
centrifugation at 100,000 × g (Beckman Optima LE-80K
Ultracentrifuge, Brea, CA, USA) overnight at 4°C fol-
lowed. Thereafter, fractions of 0.5 mL were collected and
samples were subjected to SDS-PAGE followed by Coo-
massie brilliant blue staining. Fractions showing a protein
band with an apparent molecular mass of approximately
42 kDa corresponding to VP1 protein were pooled and
diluted in DB150 buffer. The mixture was subjected to
the ultracentrifugation on CsCl gradient with densities
from 1.23 to 1.42 g/ml overnight at 100,000 × g (Beck-
man). Collected fractions were analyzed as described
above. After pooling of the VP1-containing fractions, the
second centrifugation in CsCl density gradient was per-
formed. CsCl gradient fractions containing recombinant
VP1/VP2-scFv-Fc proteins were diluted and precipitated
by ultracentrifugation for 4 h at 100,000 × g (Beckman).
The pellets were dissolved in PBS and dialyzed against
PBS overnight. The dialyzed VP1/VP2-scFv-Fc proteins
were aliquoted and lyophilized or stored in PBS in 50%
glycerol at -20
°C. The VLY-binding activity of the VLPs
harboring the scFv-Fc fragment was verified by an indir-
ect ELISA.
Determination of the quantities of VP1 and VP2-scFv-Fc
proteins in VP1/VP2-scFv-Fc VLPs
The concentration of purified VP1/VP2-scFv-Fc VLPs
VLPs (mg/ml) was determined by Bradford assay. Known
quantities of VP1/VP2-scFv-Fc VLPs (2, 2.5, 3 μg per lane)
were loaded on the SDS-PAGE gel. The quantities of VP1
and VP2-scFv-Fc proteins in each VLP preparation loaded
on the gel was determined by the densitometric scanning
of the Coomassie brilliant blue stained protein bands frac-
tionated by SDS-PAGE, using the ImageScanner III (GE
Healthcare, Little Chalfont, UK) device. Quantitative ana-
lysis was conducted with the ImageQuantTL software sup-
plied with the instrument. The determination of the
quantities of VP1 and VP2-scFv-Fc proteins in each VLP
preparation was based on the comparison with the known
quantities of VP1 and BSA proteins run in the same gel.
At least three scans of each VLP preparation were
obtained. The determined quantities of VP1 protein (1.88,
2.23 and 2.76 μg) and VP2-scFv-Fc protein (0.19, 0.22 and
0.28 μg) in these three VLP preparations corresponded to
44.92, 53.28, 65.94 pmoles of VP1 protein and 2.38 2.76,
3.51 pmoles of VP2-scFv-Fc protein as calculated in accor-
dance with their MW. As the number of molecules in one
mole is known (Avogadro constant), the number of mole-
cules of VP1 protein (2.70 × 10
13, 3.21 × 10
13,3 . 9 7×1 0
13)
and VP2-scFv-Fc protein (1.434 × 10
12,1 . 6 6×1 0
12,2 . 1 1×
10
12) in three analyzed VLP preparation samples were
determined. Assuming that 360 molecules of VP1 protein
are needed for the assembly of one VLP [33] the number
of VP1 molecules calculated above was divided by 360 to
determine the number of VLPs (7.51 × 10
10,8 . 9 1×1 0
10,
1.10 × 10
11) in three analyzed samples. The number of
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18.64, and 19.21) was calculated by dividing the number of
VP2-scFv-Fc protein molecules by the number of VLPs in
the sample. The determined average number of VP2-scFv-
Fc protein molecules per pseudotype VLP was 19.
Electron microscopy
The samples of purified recombinant VP1/VP2-scFv-Fc
protein were placed on 400-mesh carbon coated palladium
grids, negatively stained with 2% aqueous uranyl acetate
solution and examined by Morgagni 268 electron micro-
scope (FEI Inc., Hillsboro, OR, USA).
Indirect ELISA
Polystyrene microtiter plates (Nerbe plus, Winsen/Luhe,
Germany) were coated with 100 μL per well of recombi-
nant VLY diluted in coating buffer (0.05 M sodium carbo-
nate, pH 9.6) to a concentration of 5 μg/mL and incubated
overnight at 4
°C. The coated plates were blocked with 2%
BSA added 150 μL/well for 2 h at RT. Plates were rinsed
twice with PBST. Recombinant aF-scFv-Fc protein and
VP1/VP2-scFv-Fc VLPs were serially diluted in PBST,
added to the wells and incubated for 1 h at RT. Concen-
trations of aF-scFv-Fc and VP2-scFv-Fc protein displayed
on VP1/VP2-scFv-Fc VLPs ranged from 150 μg/mL to 1.2
μg/mL and from 100 μg/mL to 0.8 μg/mL, respectively.
The plates were rinsed 3 times with PBST and incubated
for 1 h with HRP-conjugated rabbit anti-human IgG (Bio-
Rad) diluted 1:1000 in PBST or HRP-conjugated goat anti-
mouse IgG (Bio-Rad) diluted 1:5000 in PBST. The plates
were rinsed 5 times with PBST. Enzymatic reaction was
visualized by the addition of 100 μL of ready-to-use TMB
substrate (Sigma-Aldrich) to each well. After 10 min of
incubation at RT, the reaction was stopped by adding 50
μL/well of 10% sulphuric acid. The optical density (OD)
was measured at 450 nm (reference filter 620 nm) in a
microplate reader (Tecan, Groedig, Austria).
In vitro hemolytic assay using human erythrocytes
In vitro hemolytic assay was performed as described pre-
viously [18]. Briefly, human blood specimens were col-
lected by a venipuncture from healthy adult volunteer and
anticoagulated by EDTA. Erythrocytes were isolated by
centrifugation and resuspended in sterile PBS. For the
VLY neutralization assay, VLY (5 ng/mL) was preincu-
bated with serial dilutions of recombinant purified aF-sFv-
Fc protein and VP1/VP2-scFv-Fc VLPs for 30 min at 20°C.
Concentrations of the aF-scFv-Fc ranged from 3.6 ng/mL
to 0.54 μg/mL (6 × 10
-11 Mt o8 . 9 6x 1 0
-9). Calculated con-
centrations of VP2-scFv-Fc on pseudotype VP1/VP2-scFv-
Fc VLPs ranged from 1 ng/mL to 33 ng/mL or 1.25 x10
-11
Mt o4 . 1×1 0
-10 M. The obtained mixture was added to
1% erythrocyte suspension in PBS. As a negative control,
recombinant VLY was added to 1 mL of 1% erythrocyte
suspension in PBS to the final concentration of 5 ng/mL.
As a positive control, VLY pre-incubated with the full-
length neutralizing mAb 9B4 was used. The concentration
of the MAb 9B4 ranged from 1 ng/ml (6.7 × 10
-11 M) to
200 ng/ml (1.33 × 10
-9 M). After 15 min of incubation at
RT the cells were pelleted by centrifugation and the
released hemoglobin was measured at 415 nm wave length
(OD415) in a microplate reader (Tecan).
Cytotoxicity assay using HeLa cell line
Adherent human epitheloid HeLa cells (ATCC Cat. No.
CCL-2) were cultivated in RPMI-1640 growth medium
(Biochrom, Berlin, Germany) supplemented with 10%
fetal bovine serum (Biochrom) and antibiotics. The cells
were grown at 37°C and 5% CO2 in 96-well plates to
approximately 70% confluence. After removing growth
medium, the cell monolayer was rinsed twice with
serum-free RPMI-1640 medium and then serum-free
RPMI-1640 medium was added to the cells (50 μL/well).
Recombinant VLY was diluted in serum-free RPMI
medium and preincubated with serial dilutions of VP1/
VP2-scFv-Fc VLPs for 30 min at RT. The concentration
o fV L Yi ne a c hi n c u b a t i o nm i x t u r ew a s6μg/mL, the
concentrations VP2-scFv-Fc displayed on VP1/VP2-
scFv-Fc VLPs ranged from 0.14 to 10 μg/mL. Fifty
microliters of each mixture were added to the wells with
HeLa cells and the plates were incubated for 1 h at 37°C
and 5% CO2. Thus, after adding the incubation mixture
(50 μL/well) to the culture of HeLa cells (50 μL/well)
the final concentration of VLY in each well was 3 μg/
mL. As a negative control, recombinant VLY at the final
concentration of 3 μg/mL was used. As a positive con-
trol, VLY pre-incubated with the full-length neutralizing
mAb 9B4 (50 μg/mL) was used. After incubation, cell
viability was determined by a colorimetric assay using 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) staining. Fifty
microliters of ready-to-use MTS solution (Promega,
Madison, WI, USA) were added to the wells and the
plates were incubated for 1 h at 37°C and 5% CO2.T h e
OD was measured at 490/630 nm wave length in a
microplate reader (Tecan). Cell viability was also
assessed microscopically at magnifications 20x and 40x
using microscope Olympus IX-70 (Olympus, Japan).
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